We aimed to assess the risk of SIS in new users of GLP-1RA when compared with sodium-glucose cotransporter 2 inhibitors (SGLT-2i) users, prescribed to treat type 2 diabetes in individuals with obesity. This evidence concerns the gene SLC5A2 and obesity due to melanocortin 4 receptor deficiency.